Prevention of hepatocellular carcinoma: A concise review of contemporary issues

Annals of Hepatology

Volumn 11, Issue 3, 2012, Pages 284-293

  Wong, Vincent Wai Sun ^a   Chan, Henry Lik Yuen ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Antiviral agents; Hepatitis B; Hepatitis B vaccines; Hepatitis C; Liver neoplasms

Indexed keywords

ADEFOVIR; AFLATOXIN; ALPHA FETOPROTEIN; BOCEPREVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C VACCINE; INTERFERON; LAMIVUDINE; PEGINTERFERON; PLACEBO; RIBAVIRIN; TELAPREVIR; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL THERAPY; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG POTENCY; EARLY DIAGNOSIS; ECHOGRAPHY; GENETIC POLYMORPHISM; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE MANPOWER; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MASS IMMUNIZATION; META ANALYSIS (TOPIC); MULTIDRUG RESISTANCE; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIMARY PREVENTION; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SECONDARY PREVENTION; TREATMENT RESPONSE; TREND STUDY; VIRUS CARCINOGENESIS;

EID: 84859308589     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)30922-6     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-23.
4. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001; 94: 290-6.
5. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepatol 2009; 24: 346-53.
6. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11: 97-107.
7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-38.
8. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 2010; 52: 594-604.
9. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153-61.
10. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303: 833-41.
11. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, Hilleman MR. Human hepatitis B vaccine from recombinant yeast. Nature 1984; 307: 178-80.
12. Beasley RP, Hwang LY, Lee GC, Lan CC, Roan CH, Huang FY, Chen CL. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2: 1099-102.
13. Coursaget P, Leboulleux D, Soumare M, le Cann P, Yvonnet B, Chiron JP, Coll-Seck AM, et al. Twelve-year follow-up study of hepatitis B immunization of Senegalese infants. J Hepatol 1994; 21: 250-4.
14. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, Tsai KS, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001; 135: 796-800.
15. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003; 187: 134-8.
16. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997; 336: 1855-9.
17. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-55.
18. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroenterol Hepatol 2011; 25: 657-63.
19. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis 2009; 200: 39-47.
20. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-7.
21. Mohamed R, Desmond P, Suh DJ, Amarapurkar D, Gane E, Guangbi Y, Hou JL, et al. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol 2004; 19: 958-69.
22. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
23. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
24. Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26: 177-82.
25. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
26. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, openlabel study. Hepatology 2011; 54: 91-100.
27. Gane E, Chan HL, Choudhuri G, Suh DJ, Chutaputti A, Safadi R, Tanwandee T, et al. Treatment of decompensated HBV-cirrhosis: results from 2-years randomized trial with telbivudine or lamivudine. J Hepatol 2010; 52 (Suppl. 1): S4.
28. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.